ScreenerHero

SION Sionna Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · sionnatx.com
4.820USD+1.47%Mkt Cap: 217.92M $P/E: —

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-dire…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap217.92M USD
Enterprise Value11.80M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-75.27M USD
Revenue/Share—
Last Price4.820 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees59
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.13
PEG—
EV/EBITDA-0.11
EV/Revenue—
P/S—
P/B0.81
EPS (TTM)-2.12
EPS (Forward)-2.23
52W Range
4.0102% of range54.97
52W High54.97 USD
52W Low4.010 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-24.53%
ROA-23.09%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-66.30M USD
CapEx (TTM)377.00K USD
FCF Margin—
FCF Yield-20.85%
Net Debt-202.96M USD
Net Debt/EBITDA1.86
Balance Sheet
Debt/Equity0.03
Current Ratio20.05
Quick Ratio19.57
Book Value/Sh5.88 USD
Cash/Share4.67 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.7 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)21.00 USD
Upside (mean)+335.7%
Target Range5.000 USD – 63.00 USD
5.000+335.7% to mean63.00
# Analysts7
Ownership
Shares Out.45.21M
Float20.47M
Insiders7.88%
Institutions99.24%
Short Interest
Short Ratio2.7d
Short % Float14.23%
Short % Out.8.77%
Shares Short3.97M
Short (prev mo.)4.25M
Technical
SMA 5014.46 (-66.7%)
SMA 20033.61 (-85.7%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)1.33M
Avg Vol (10d)1.21M
Technical Indicators
RSI (14)27.3
MACD-1.9960
MACD Signal-2.5167
MACD Hist.+0.5207
BB Upper8.188 USD
BB Middle5.937 USD
BB Lower3.686 USD
BB Width75.83%
ATR (14)0.7562 USD
Vol Ratio (20d)0.60x